You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Dow
McKesson
Colorcon
Johnson and Johnson

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-04-30 1 of Vanda’s U.S. Patent Nos. RE46,604 (“the RE604 patent”); 9,060,995 (“the ’995 patent”); 9,539,234 (… V. THE PATENTS-IN-SUIT (U.S. PATENT NOS. RE46,604; 9,060,995; 9,539,234; 9,549,913;… U.S. Patent No. 9,060,995 29. Vanda is the owner… (“the ’234 patent”); 9,549,913 (“the ’913 patent”); 9,730,910 (“the ’910 patent”); and Case 1:18-cv-00651…#: 2 9,855,241 (“the ’241 patent”) (collectively “the Asserted Patents”), which, in relevant part, External link to document
2019-12-03 113 Notice of Service U.S. Patent No. 10,071,977; (2) Defendants' Amended Invalidity Contentions Regarding U.S. Patent No. 10,149,829… 30 April 2018 1:18-cv-00651 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2019-12-10 114 Notice of Service Supplemental Infringement Contentions for U.S. Patent No. 10,071,977 to Teva; and (2) Vanda's Supplemental Infringement…Infringement Contentions for U.S. Patent No. 10,071,977 to MSN filed by Vanda Pharmaceuticals Inc..(Fahnestock… 30 April 2018 1:18-cv-00651 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2019-12-23 117 Notice of Service Invalidity Contentions Concerning U.S. Patent No. 10,071,977 2) Defendants Second Amended Invalidity …Invalidity Contentions Regarding U.S. Patent No. 10,149,829 3) Defendants Third Amended Invalidity Contentions … 30 April 2018 1:18-cv-00651 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2020-01-31 121 Notice of Service Regarding Infringement by Teva of U.S. Patent No. 10,071,977 filed by Vanda Pharmaceuticals Inc..(Jacobs… 30 April 2018 1:18-cv-00651 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2020-02-04 122 Notice of Service Report of Dr. Robert B. Perni Regarding U.S. Patent No. 10,071,977 (2) First Expert Report of Dr. Jonathan … 30 April 2018 1:18-cv-00651 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2020-03-30 126 Notice of Service Perni Regarding Non-Infringement of U.S. Patent No. 10,071,977 3) First Expert Report of Dr. John W. Winkelman… 30 April 2018 1:18-cv-00651 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Moodys
Dow
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.